(Q41562000)

English

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients

scientific article published on 20 January 2015

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

3 October 2017

Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients (English)

1 reference

Europe PubMed Central

3 October 2017

beta thalassemia

1 reference

based on heuristic

inferred from title

author name string

Mohsen S Elalfy

1

1 reference

Europe PubMed Central

3 October 2017

Amira M Adly

2

1 reference

Europe PubMed Central

3 October 2017

Yasser Wali

3

1 reference

Europe PubMed Central

3 October 2017

Samir Tony

4

1 reference

Europe PubMed Central

3 October 2017

Ahmad Samir

5

1 reference

Europe PubMed Central

3 October 2017

Yasmine I Elhenawy

6

1 reference

Europe PubMed Central

3 October 2017

publication date

20 January 2015

1 reference

Europe PubMed Central

3 October 2017

European Journal of Haematology

1 reference

Europe PubMed Central

3 October 2017

95

1 reference

Europe PubMed Central

3 October 2017

5

1 reference

Europe PubMed Central

3 October 2017

411-420

1 reference

Europe PubMed Central

3 October 2017

Longitudinal study of survival and causes of death in patients with thalassemia major in Greece

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Labile plasma iron in iron overload: redox activity and susceptibility to chelation

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Intracellular labile iron.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Deferoxamine pharmacokinetics

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

LPI-labile plasma iron in iron overload

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Treating thalassemia major-related iron overload: the role of deferiprone

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

The effect of deferasirox on cardiac iron in thalassemia major: impact of total body iron stores

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Satisfaction and adherence in patients with iron overload receiving iron chelation therapy as assessed by a newly developed patient instrument

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Histological grading and staging of chronic hepatitis

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Efficacy and safety of deferasirox doses of >30 mg/kg per d in patients with transfusion-dependent anaemia and iron overload

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Inflammation and oxidant-stress in beta-thalassemia patients treated with iron chelators deferasirox (ICL670) or deferoxamine: an ancillary study of the Novartis CICL670A0107 trial

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Oral chelators in transfusion-dependent thalassemia major patients may prevent or reverse iron overload complications.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Action of chelators in iron-loaded cardiac cells: Accessibility to intracellular labile iron and functional consequences

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Combining two orally active iron chelators for thalassemia.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Continued improvement in myocardial T2* over two years of deferasirox therapy in β-thalassemia major patients with cardiac iron overload

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Importance of optimal dosing ≥ 30 mg/kg/d during deferasirox treatment: 2.7-yr follow-up from the ESCALATOR study in patients with β-thalassaemia

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA).

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

A randomized controlled 1-year study of daily deferiprone plus twice weekly desferrioxamine compared with daily deferiprone monotherapy in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Mechanisms for the shuttling of plasma non-transferrin-bound iron (NTBI) onto deferoxamine by deferiprone.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Recent insights into interactions of deferoxamine with cellular and plasma iron pools: Implications for clinical use.

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Health-Related Quality of Life, Treatment Satisfaction, Adherence and Persistence in β-Thalassemia and Myelodysplastic Syndrome Patients with Iron Overload Receiving Deferasirox: Results from the EPIC Clinical Trial

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

A new tool for the assessment of satisfaction with iron chelation therapy (ICT-Sat) for patients with β-thalassemia major

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Patient-reported outcomes of deferasirox (Exjade, ICL670) versus deferoxamine in sickle cell disease patients with transfusional hemosiderosis. Substudy of a randomized open-label phase II trial

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Deviating from safety guidelines during deferiprone therapy in clinical practice may not be associated with higher risk of agranulocytosis

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

How I treat transfusional iron overload

1 reference

https://api.crossref.org/works/10.1111%2FEJH.12507

21 January 2018

Identifiers

10.1111/EJH.12507

1 reference

Europe PubMed Central

3 October 2017

1 reference

Europe PubMed Central

3 October 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q41562000&oldid=2130460782"